Jesteśmy na EACR w Barcelonie

Można nas spotkać na konferencji The European Association for Cancer Research w Barcelonie (7-10 lipca), gdzie prezentujemy wyniki naszych badań: NPM-ALK I1171T mutation confers resistance to crizotinib in anaplastic large cell lymphoma . Differential gene transcription response to the treatment with JAK2 inhibitors – Ruxolitinib, SAR302503 and LY2784544 . Gene silencing of β-catenin inhibits growth of Wnt/β-catenin pathway dependent colon cancer cell lines .

The release as fetched from its publisher. celonpharma.com ↗